Helicobacter pylori Infections - Pipeline Review, H1 2016

  • ID: 3635611
  • Report
  • 71 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • EpiVax, Inc.
  • Frost Biologic, Inc.
  • ImevaX GmbH
  • ImmunoBiology Limited
  • RedHill Biopharma Ltd.
  • Sequella, Inc.
  • MORE
Helicobacter pylori Infections - Pipeline Review, H1 2016

Summary

The report ‘Helicobacter pylori Infections - Pipeline Review, H1 2016’, provides an overview of the Helicobacter pylori Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Helicobacter pylori Infections
- The report reviews pipeline therapeutics for Helicobacter pylori Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Helicobacter pylori Infections therapeutics and enlists all their major and minor projects
- The report assesses Helicobacter pylori Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Helicobacter pylori Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Helicobacter pylori Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Helicobacter pylori Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • EpiVax, Inc.
  • Frost Biologic, Inc.
  • ImevaX GmbH
  • ImmunoBiology Limited
  • RedHill Biopharma Ltd.
  • Sequella, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Helicobacter pylori Infections Overview

Therapeutics Development

Pipeline Products for Helicobacter pylori Infections - Overview

Pipeline Products for Helicobacter pylori Infections - Comparative Analysis

Helicobacter pylori Infections - Therapeutics under Development by Companies

Helicobacter pylori Infections - Therapeutics under Investigation by Universities/Institutes

Helicobacter pylori Infections - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Helicobacter pylori Infections - Products under Development by Companies

Helicobacter pylori Infections - Products under Investigation by Universities/Institutes

Helicobacter pylori Infections - Companies Involved in Therapeutics Development

Daewoong Pharmaceutical Co., Ltd.

Debiopharm International S.A.

EpiVax, Inc.

Frost Biologic, Inc.

ImevaX GmbH

ImmunoBiology Limited

RedHill Biopharma Ltd.

Sequella, Inc.

Sigmoid Pharma Limited

Helicobacter pylori Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(amoxicillin sodium + omeprazole sodium + rifabutin) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Debio-1453 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DWJ-1325 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FROST-900 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Helicobacter pylori [strain Hel-305] (multivalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Helicobacter pylori vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Helicobacter pylori vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Helicobacter pylori vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Helicobacter pylori vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HPi-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IMX-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Helicobacter Pylori Infections - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SQ-109 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Helicobacter pylori Infections - Recent Pipeline Updates

Helicobacter pylori Infections - Dormant Projects

Helicobacter pylori Infections - Product Development Milestones

Featured News & Press Releases

Sep 08, 2015: RedHill Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study’s Positive Results

Aug 26, 2015: Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for treatment of H. pylori infection

Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection

Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection

Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study

Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results

May 18, 2015: RedHill Biopharma’s Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market

May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study

Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection

Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Helicobacter pylori Infections, H1 2016

Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Helicobacter pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016

Helicobacter pylori Infections - Pipeline by Debiopharm International S.A., H1 2016

Helicobacter pylori Infections - Pipeline by EpiVax, Inc., H1 2016

Helicobacter pylori Infections - Pipeline by Frost Biologic, Inc., H1 2016

Helicobacter pylori Infections - Pipeline by ImevaX GmbH, H1 2016

Helicobacter pylori Infections - Pipeline by ImmunoBiology Limited, H1 2016

Helicobacter pylori Infections - Pipeline by RedHill Biopharma Ltd., H1 2016

Helicobacter pylori Infections - Pipeline by Sequella, Inc., H1 2016

Helicobacter pylori Infections - Pipeline by Sigmoid Pharma Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Helicobacter pylori Infections Therapeutics - Recent Pipeline Updates, H1 2016

Helicobacter pylori Infections - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Helicobacter pylori Infections, H1 2016

Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Daewoong Pharmaceutical Co., Ltd.
Debiopharm International S.A.
EpiVax, Inc.
Frost Biologic, Inc.
ImevaX GmbH
ImmunoBiology Limited
RedHill Biopharma Ltd.
Sequella, Inc.
Sigmoid Pharma Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll